Our finding in vitro revealed that sage MetOH extract has no effect on lipolytic activity in 267 3T3-L1 cells; however sage-treated animals had a decrease in plasma NEFA and triglycerides 268 levels, suggesting an inhibition of lipolysis. This is clearly due to the facts that it is not 269 always possible to reproduce in vivo results observed in vitro. In fact, 3T3-L1 cells differ from 270 adipocytes and there is an indirect influence of actions on other tissues on adipocytes. 271 In addition, the plant extract reduced lipogenesis in a concentration-response manner 272 when the cells were treated during both the differentiation and nutrition steps. Obesity is a 273 pathological disorder characterized by excessive fat storage endogenously; and here we 274 demonstrate that sage MetOH extract exhibited significant in vitro inhibition of lipid droplet 275 accumulation in mature adipocytes. However, sage extract was more efficient on reducing lipid 276 accumulation when it was added to both differentiation and nutrition media ( 
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The efficacy of S. officinalis in the prevention of lipid accumulation within 3T3-L1 283 adipocytes is consistent with it reducing bodyweight gain (related to adipose tissue hypertrophy) 284 in HFD mice treated with low dose sage MetOH extract. Nevertheless, this anti-obesity effect of 285 sage might be due also to reduced food intake (Table 1) . 286 In HFD animals, the treatment with low dose MetOH extract for two weeks, resulted in 287 an improvement of glucose tolerance, and a reduction of plasma insulin levels in response to 288 glucose load. After 3 weeks of treatment, the HOMA-IR index reflecting insulin resistance was 
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Our evidence from blood glucose and plasma insulin levels that low dose sage improved 300 insulin sensitivity was confirmed by an insulin tolerance test conducted after 4 weeks of 301 treatment. Thus, mice treated with sage low dose exhibited a significant decrease in blood 302 glucose levels in response to intraperitoneal insulin injection. This test, to the best of our 303 knowledge, was performed on sage-treated mice for the first time and confirms an insulin-304 sensitizer effect of sage extract. Moreover the chronic treatment with low sage dose resulted in a 305 significant decrease in fed plasma insulin levels. A similar effect was observed in the 306 rosiglitazone-treated mice.
307
Sage, at the high dose has not shown the beneficial effects observed with low dose, on 308 glucose tolerance, insulin sensitivity, bodyweight gain and food intake. This might be explained 309 by an increased daily intake in palmitic acid (PA). According to the content in PA of sage 310 MetOH extract (Table 2) , the daily intake of PA, in high dose sage treated mice was 277 μg.kg -1 , 1 
Figure 2
Oral glucose tolerance test (A) and plasma insulin levels 30 min before and after glucose load (B) HFD mice were treated for 2 weeks with sage MetOH extract (100 mg/kg/day and 400 mg/kg/day), and rosiglitazone (3 mg/kg/day). Glucose solution (2.5g/kg) was given orally after 5 hours fast. Blood glucose values represent mean + SEM (n = 7 in group A and n = 8 in groups B, C and D), and statistical significance compared with the vehicle group data is shown as: * P <0.05, ** P <0.01 and *** P <0.001.
Figure 3
Effects of Salvia officinalis MetOH extract on fasted blood glucose, and insulin sensitivity Blood glucose levels were measured after a 5-hour fast (A), and insulin sensitivity is represented by the product of blood glucose and plasma insulin values (B), after 3 weeks of treatment with sage MetOH extract (100 mg/kg/day and 400 mg/kg/day), and rosiglitazone (3 mg/kg/day). Blood glucose levels were observed during the Insulin tolerance test (C), performed at day 29 of treatment. Insulin (Actrapid, 0.75 UI/kg/ml in saline) was injected intraperitoneally to 5-hour fasted mice. All values are means ± SEM (n = 7 in group A and n = 8 in groups B, C and D). *P <0.05, **P <0.01 and *** P <0.001 as compared to the vehicle-treated group.
Figure 4
Plasma levels of insulin (A) , leptin (B) ,total cholesterol ( C), HDL-Cholesterol (D) , Triglycerides (E) ,and NEFA (F), after 5 weeks of treatment with sage MetOH extract .
The plasma samples were collected from fed mice, at the termination day, after 5 weeks treatment with sage MetOH extract (100 mg/kg/day and 400 mg/kg/day), and rosiglitazone (3 mg/kg/day). Values represent mean + SEM (n = 7 in group A and n = 8 in groups B, C and D), and statistical significance compared with the vehicle group data is shown as: * P <0.05 and ** P <0.01.
Figure 5
Plasma levels of 'pro-and anti-inflammatory' cytokines after chronic treatment with low dose of sage MetOH extract Comparison between the levels of pro-inflammatory (A), and anti-inflammatory cytokines (B), measured in plasma samples collected from fed mice treated for 5 weeks with sage extract low dose sage MetOH extract (100 mg/kg/day), and mice control group (water: 10 ml/kg/day). Values represent mean + SEM (n = 7 in group A and n = 8 in group B) , and statistical significance compared with the vehicle group data is shown as: *P <0.05 and ** P <0.01.
Figure 6(on next page)

Sage fatty acids profile analysed by Gas Chromatography
Typical chromatogram of sage fatty acid profile analyzed by GC. The composition of fatty acid in sage MetOH extract contains different classes ranging from C4:0 to C24:0. FA methyl esters (FAMEs) were identified by comparing each sample with a standard FAME reference mixture, and FA acid peak areas were calculated using HP ChemStation software
